Lilly CEO Lechleiter On Drug Pricing: “The Facts Tell Us A Different Story”
This article was originally published in The Pink Sheet Daily
Industry needs to do more, but be “careful and thoughtful” about responding to drug pricing criticism, Lilly CEO John Lechleiter said during the company’s third quarter call. The company’s SGLT-2 inhibitor Jardiance is already seeing a bump in prescriptions following the release of positive CV outcomes data.
You may also be interested in...
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.